Healx vs Insilico Medicine

Insilico Medicine has a disclosed valuation of $1.2B, while Healx's valuation is not publicly available, making a direct size comparison difficult. Insilico Medicine employs 350 people.

Insilico Medicine has raised more in total funding at $403M, compared to Healx's $47M — a gap of $356M. Combined, the two companies have completed 3 known funding rounds.

Insilico Medicine holds the higher Awaira Score at 67/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 12-point gap that reflects meaningful differences in scale or traction.

Healx was founded by Tim Guilliams in 2014. Insilico Medicine was founded by Alex Zhavoronkov in 2014. Visit each company's profile on Awaira for a full founder biography.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company leverages artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels.

Both Healx and Insilico Medicine were founded in the same year — 2014. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Healx has approximately 1-50 employees, while Insilico Medicine has approximately 350. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and Insilico Medicine are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.